How long and how well: Oncologists' attitudes toward the relative value of life-prolonging v. quality of life-enhancing treatments

Medical Decision Making

Volumn 31, Issue 3, 2011, Pages 380-385

  Kozminski, Michael A ^a   Neumann, Peter J ^b   Nadler, Eric S ^c   Jankovic, Aleksandra ^a   Ubel, Peter A ^a,d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

cost effectiveness; drug therapy; medical economics; medical oncology; quality of life

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; DECISION MAKING; ECONOMICS; FEMALE; HEALTH CARE COST; HEALTH PERSONNEL ATTITUDE; HUMAN; INFORMATION PROCESSING; MALE; MIDDLE AGED; NEOPLASM; ONCOLOGY; PHYSICIAN; PROGNOSIS; PSYCHOLOGICAL ASPECT; QUALITY ADJUSTED LIFE YEAR; SOCIOECONOMICS; TIME; UNITED STATES;

ATTITUDE OF HEALTH PERSONNEL; COST-BENEFIT ANALYSIS; DATA COLLECTION; DECISION MAKING; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; NEOPLASMS; PHYSICIANS; PROGNOSIS; QUALITY-ADJUSTED LIFE YEARS; TIME FACTORS; UNITED STATES; VALUE OF LIFE;

EID: 79957597580     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X10385847     Document Type: Article

References (37)

1. Bodenheimer T. High and rising health care costs. Part 1: Seeking an explanation. Ann Intern Med. 2005;142:847-54.
2. The right question. The Economist. October 20, 2007.
3. Associated Press. Docs to weigh costs in choosing cancer treatment. CNN.com. March 25, 2008 ed: CNN; 2008.
4. Kolata G, Pollack A. Costly Cancer Drug Offers Hope, but Also a Dilemma. The New York Times. July 6, 2008.
5. Bach PB. Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med. 2009;360:626-33.
6. Baicker K. Formula for compromise: expanding coverage and promoting high-value care. Health Affairs. 2008;27:658-66. (Pubitemid 351770231)
7. Ramsey S, Willke R, Briggs A, et al. Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-CEA Task Force Report. Value Health. 2005;8:521-33. (Pubitemid 41727304)
8. Earle CC, Chapman RH, Baker CS, et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol. 2000;18:3302-17.
9. Neumann PJ, Greenberg D, Olchanski NV, Stone PW, Rosen AB. Growth and quality of the cost-utility literature, 1976-2001. Value Health. 2005;8:3-9.
10. Brauer CA, Rosen AB, Greenberg D, Neumann PJ. Trends in the measurement of health utilities in published cost-utility analyses. Value Health. 2006;9:213-8. (Pubitemid 44126775)
11. Dean HE. Political and ethical implications of using quality of life as an outcome measure. Semin Oncol Nurs. 1990;6:303-8.
12. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ. 1998;317:771-5. (Pubitemid 28427226)
13. Steer CB, Marx GM, Harper PG. Is there quality in clinical benefit? Ann Oncol. 2001;12:1191-3.
14. Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist. 2006;11:90-5.
15. Asch DA, Jedrziewski MK, Christakis NA. Response rates to mail surveys published in medical journals. J Clin Epidemiol. 1997;50:1129-36.
16. Ubel PA, Arnold RM. The unbearable rightness of bedside rationing. Arch Intern Med. 1995;155:1837-42.
17. De Maio E, Perrone F, Bisagni G, Boni C. The new drugs advent: clinical or economic outcomes? [symposium article]. Ann Oncol. 2006;17(suppl 2):ii88-ii90.
18. Marino P. Measuring the cost of chemotherapy is important, but it is not enough. Ann Oncol. 2008;19:409-10. (Pubitemid 351325659)
19. Earle CC, Coyle D, Evans WK. Cost-effectiveness analysis in oncology [review]. Ann Oncol. 1998;9:475-82.
20. Patel M, Lypson M, Davis M. Medical student perceptions of education in health care systems. Acad Med. 2009;84:1301-6.
21. Ubel PA. Pricing Life: Why It's Time for Health Care Rationing. Cambridge (MA): Bradford Books, MIT Press; 2000.
22. Gold MR, Siegel JE, Russell LB, Weinstein M, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
23. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20:332-42. (Pubitemid 30479101)
24. Cairns J. Providing guidance to the NHS: The Scottish Medicines Consortium and the National Institute for Clinical Excellence compared. Health Policy. 2006;76:134-43. (Pubitemid 43330597)
25. Raftery J. Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand. Med J Aust. 2008;188:26-8.
26. Rocchi A, Menon D, Verma S, Miller E. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond. Value Health. 2008;11:771-83. (Pubitemid 352032812)
27. Mason A, M D. Public funding of new cancer drugs: is NICE getting nastier? Eur J Cancer. 2009;45:1188-92.
28. Cookson R, McCabe C, Tsuchiya A. Public healthcare resource allocation and the rule of rescue. J Med Ethics. 2008;34:540-4.
29. Cella DF, Tulsky DS. Quality of life in cancer: definition, purpose, and method of measurement. Cancer Invest. 1993;11:327-36. (Pubitemid 23161192)
30. American Society of Clinical Oncology (ASCO) Cost of Care Task Force. Cost of Cancer Care. 2009; Available from: www.asco.org/costofcare. Accessed June 14, 2009.
31. Alexander G, Casalino L, Meltzer D. Patient-physician communication about out-of-pocket costs. JAMA. 2003;290:953-8. (Pubitemid 37430470)
32. Alexander G, Casalino L, Tseng C, McFadden D, Meltzer D. Barriers to patient-physician communication about out-of-pocket costs. J Gen Intern Med. 2004;19:856-60. (Pubitemid 39096358)
33. Schrag D, Hanger M. Medical Oncologists' Views on Communicating With Patients About Chemotherapy Costs: A Pilot Survey. J Clin Oncol. 2007;25:233-7. (Pubitemid 350003040)
34. Neumann P, Palmer J, Abrahams D, Ubel PA. Struggling with expensive new cancer therapies: a national survey of oncologists. Health Affairs. 2010;29:196-202.
35. Kaplan RI, Atkins CJ. The well-year of life as a basis for patient decision-making. Patient Educ Couns. 1989;13:281-95. (Pubitemid 19130056)
36. La Puma J, Lawlor EF. Quality-adjusted life-years. Ethical implications for physicians and policymakers. JAMA. 1990;263:2917-21.
37. Johnstone MJ. Quality versus quantity of life: who should decide? Aust J Adv Nurs. 1988;6:30-7.